Cardeas Pharma

About Cardeas Pharma

Cardeas Pharma was a biopharmaceutical company established in 2010, focusing on developing inhaled antibiotics for severe, hospital-acquired respiratory infections caused by multi-drug resistant (MDR) organisms. The Seattle-based startup was led by CEO Bruce Montgomery, a veteran in the biotech space known for his previous roles at Corus Pharma and PathoGenesis Corporation. His expertise in respiratory drug development was a key factor for investors. The company secured significant venture capital, raising a total of $53.6 million over several funding rounds, including a notable $34 million Series B in 2013 led by H.I.G. BioVentures. This funding was aimed at advancing its lead product through clinical trials.

The company's core business revolved around addressing critical unmet needs for patients in intensive care settings, particularly those on mechanical ventilators who are susceptible to pneumonia. Cardeas Pharma's primary product was the Amikacin Fosfomycin Inhalation System (AFIS). This system was a combination therapy consisting of two antibiotics, amikacin and fosfomycin, formulated into an aerosol. The drug was delivered directly to the lungs using a proprietary eFlow® Inline Nebulizer System, developed in partnership with PARI Pharma. This device was designed to create fine, uniform droplets to ensure the medication reached the small airways and alveoli effectively, intended as an adjunctive treatment to standard IV antibiotics. The combination of these two drugs showed synergistic activity against highly resistant Gram-negative bacteria.

Cardeas progressed its product through clinical development, completing a Phase 1b study and advancing into Phase 2 trials to evaluate safety and efficacy. In 2014, the U.S. FDA granted the Amikacin Fosfomycin Inhalation System a Qualified Infectious Disease Product (QIDP) designation, which provides incentives for the development of new antibacterial drugs. Despite these milestones and promising early results, the company ultimately ceased operations around December 2017. A Phase 2 trial, while demonstrating a reduction in bacterial load, did not show a statistically significant improvement in clinical outcomes compared to the placebo group.